Lung Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Lung surgery is a major thoracic procedure performed to diagnose or treat diseases of the lungs, pleura, and airways. It ranges from minor procedures such as pleural biopsy and drainage to major resections removing a lobe (lobectomy), two lobes (bilobectomy), a single pulmonary segment (segmentectomy), or an entire lung (pneumonectomy). The extent of resection is determined by the location and extent of disease, the patient's pre-operative lung function, cardiac reserve, and overall performance status.

Conventional lung surgery has historically been performed via thoracotomy — a large lateral chest incision with rib spreading that provides direct access to the lung. Over the past two decades, video-assisted thoracoscopic surgery (VATS) — using small port incisions and a camera — has largely replaced open thoracotomy for anatomical lung resections at high-volume thoracic centres, offering equivalent oncological outcomes with significantly less pain, shorter hospital stay, reduced blood loss, and faster return to full activity. Robotic-assisted thoracic surgery (RATS), using the da Vinci system, further enhances visualisation and instrument dexterity, particularly for complex hilar dissections and sleeve resections.

The most common indication for lung surgery is non-small cell lung cancer (NSCLC), where complete surgical resection remains the only potentially curative treatment for early-stage disease. A multidisciplinary tumour board — involving thoracic surgery, oncology, pulmonology, radiology, and pathology — guides treatment decisions before any surgical intervention. Other major indications include pulmonary metastasectomy, lung abscess, empyema, bronchiectasis, bullous emphysema, and benign tumours.

Primary lung cancer — predominantly NSCLC including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma — in clinical Stage I and II (and selected Stage IIIA) is the dominant indication for curative-intent lung surgery. Complete anatomical resection with mediastinal lymph node dissection and negative surgical margins (R0 resection) provides the best chance of long-term cure in early-stage disease, with five-year survival rates of 70–90% for Stage IA. Pulmonary metastasectomy — surgical removal of lung metastases from colorectal, renal, sarcoma, or other primary cancers — is indicated when systemic disease is controlled, the number of metastases is limited, and adequate pulmonary reserve permits resection.

Benign conditions treated surgically include pulmonary carcinoid tumours, lung abscess refractory to antibiotics, empyema necessitans, bronchiectasis with focal disease causing recurrent severe haemoptysis or infection, bullous emphysema causing spontaneous pneumothorax or compressing adjacent lung tissue, and pulmonary sequestration. Diagnostic surgical procedures — VATS lung biopsy for interstitial lung disease — are performed when bronchoscopic and CT-guided biopsies are non-diagnostic. Chest wall tumours, thymomas, and mediastinal masses may also require thoracic surgical approaches.

Pre-operative assessment for lung surgery centres on pulmonary function testing and cardiopulmonary exercise testing to ensure the patient will have sufficient residual lung function and cardiac reserve after resection. A post-operative predicted FEV1 (ppoFEV1) above 40% predicted and a predicted diffusing capacity (ppoDLCO) above 40% are generally considered the minimum thresholds for lobectomy without unacceptable risk of respiratory failure. Peak oxygen consumption on exercise testing above 15 mL/kg/min suggests adequate cardiopulmonary reserve. Patients with lower predicted residual function may be considered for lesser resections (segmentectomy, wedge), though oncological adequacy must be balanced against functional preservation. Overall fitness, smoking history, age, cardiac comorbidities, and nutritional status also inform the surgical risk assessment.

Contraindications to major lung resection include ppoFEV1 below 30%, severe pulmonary hypertension, recent myocardial infarction or unstable angina, severely impaired cardiac function (EF below 35%), active uncontrolled infection remote from the thorax, and metastatic disease beyond resectable pulmonary deposits. Patients with borderline lung function who require resection for cancer may be considered after a period of pulmonary rehabilitation and smoking cessation to optimise pre-operative function. Small cell lung cancer (except very early-stage) is generally not treated surgically due to its early systemic dissemination.

Lobectomy — removal of an entire lobe — is the standard anatomical resection for NSCLC up to 4 cm in size, providing the best local recurrence control. VATS lobectomy, performed through three or four small port incisions without rib spreading, is the preferred technique at experienced centres; randomised data and large registry studies show equivalent five-year survival to open lobectomy with substantially lower morbidity. Robotic lobectomy offers enhanced three-dimensional visualisation and wristed instrument articulation, facilitating complex hilar dissection and sleeve resections in anatomically challenging cases. Thoracotomy — posterolateral or anterolateral — remains necessary for complex cases requiring sleeve resection of the bronchus or pulmonary artery, invasion of adjacent structures, or chest wall involvement.

Segmentectomy (anatomical sub-lobar resection) is increasingly favoured for small (below 2 cm) peripherally located Stage IA adenocarcinomas, particularly in patients with compromised lung function. JCOG0802 trial data demonstrate non-inferiority of segmentectomy to lobectomy for small peripheral NSCLC with a pure ground-glass opacity component, reducing the functional sacrifice. Pneumonectomy — complete lung removal — is reserved for central tumours involving the main bronchus or cases where lobar anatomy precludes lobectomy; it carries significantly higher morbidity and mortality than lobectomy. Pleurectomy/decortication and extrapleural pneumonectomy are performed for malignant pleural mesothelioma at specialist centres.

Surgical resection offers the highest probability of long-term cure for early-stage non-small cell lung cancer. Five-year survival after complete resection for Stage IA1 NSCLC (tumour below 1 cm) approaches 90%, and remains approximately 70% for Stage IB (tumours 2–4 cm). For Stage II disease, adjuvant platinum-based chemotherapy after complete resection further reduces the risk of recurrence, with evidence-based improvements in five-year survival of approximately 5%. In patients undergoing pulmonary metastasectomy for colorectal cancer with limited lung metastases, five-year survival of 35–50% is achievable at specialist centres with appropriate patient selection.

For benign conditions, lung surgery provides definitive resolution that medical therapy cannot achieve. Patients with recurrent spontaneous pneumothorax achieve near-complete prevention of further episodes after thoracoscopic pleurectomy and bullectomy, avoiding the morbidity of repeated chest drain insertions. Removal of a lung abscess or area of destroyed lung in bronchiectasis eliminates the source of chronic infection, reduces antibiotic dependency, and significantly improves quality of life. VATS resection is associated with lower rates of post-thoracotomy pain syndrome compared to open thoracotomy — a meaningful benefit as chronic post-thoracotomy pain affects up to 50% of patients after conventional open surgery.

Operative mortality for VATS lobectomy at high-volume centres is 0.5–1.5%, rising to 5–8% for pneumonectomy due to the greater reduction in cardiopulmonary reserve. Prolonged air leak — escape of air from the cut lung surface through the drainage tube for more than five days — is the most common complication after lobectomy, affecting 5–15% of patients, and is usually managed conservatively. Atrial fibrillation develops in 10–20% of patients after major lung resection, particularly after pneumonectomy, and typically resolves with rate-control or cardioversion within days to weeks.

Post-pneumonectomy pulmonary oedema — a form of acute lung injury affecting the remaining lung — is a serious complication with high mortality occurring in approximately 2–5% of pneumonectomies. Bronchopleural fistula — dehiscence of the bronchial stump allowing air to enter the pleural space — is a rare (1–3%) but life-threatening complication requiring immediate surgical or bronchoscopic intervention. Empyema (infection of the pleural cavity), phrenic nerve injury causing diaphragmatic palsy, and recurrent laryngeal nerve injury causing vocal cord paralysis are recognised though uncommon complications of mediastinal nodal dissection and complex resections. Post-thoracotomy pain syndrome — chronic pain persisting beyond three months — affects up to 50% of patients after open surgery but is substantially less common after VATS.

After VATS lobectomy, the average hospital stay is three to five days; open thoracotomy patients typically remain seven to ten days. One or two intercostal drains are placed intraoperatively to drain air and fluid from the pleural space and are removed once drainage is minimal and air leak has resolved, usually within two to four days. Pain management in the immediate post-operative period employs thoracic epidural analgesia or paravertebral nerve blocks, transitioning to oral analgesia on discharge. Respiratory physiotherapy — deep breathing exercises and incentive spirometry — commences on the day of surgery to prevent atelectasis and pneumonia.

For lung cancer patients, CT surveillance is performed every three to six months for the first two years, then annually to detect ipsilateral recurrence or new contralateral lung primaries. Pulmonary function testing is repeated at six to twelve weeks to document the actual functional impact of resection. Patients who smoked are strongly advised on smoking cessation to reduce contralateral lung cancer risk and improve cardiopulmonary reserve. Physical rehabilitation over three to six months restores exercise tolerance; most patients recover approximately 80–85% of their pre-operative lung function after lobectomy. Return to sedentary work typically occurs within four to six weeks of VATS resection and six to eight weeks after open thoracotomy.

Lung surgery costs in the United States range from USD 40,000–100,000 for lobectomy depending on approach (VATS versus open), hospital setting, and post-operative course. Complex resections, pneumonectomy, or sleeve procedures can exceed USD 150,000. In the UK, NHS patients receive care without direct charge, but private thoracic surgery costs GBP 20,000–50,000. Costs are driven by surgical time, intensive care unit stays, stapler and port costs (for VATS), and pathology.

In India, leading thoracic surgery centres at Apollo Hospitals, Tata Memorial Hospital (Mumbai), and Fortis Hospitals offer VATS lobectomy for USD 5,000–12,000 — a saving of over 80% versus US prices. Thailand (Bumrungrad International) charges USD 12,000–25,000; Turkey (Acibadem, Ankara City Hospital) USD 8,000–18,000; and Poland EUR 8,000–15,000. Medical tourism for thoracic surgery is well-established for patients from the Middle East, UK, and sub-Saharan Africa. Patients should verify that the international centre has a dedicated multidisciplinary thoracic oncology team, an active VATS programme with documented high-volume experience, and a clear arrangement for post-operative pathology review and adjuvant chemotherapy if required.

Stereotactic body radiotherapy (SBRT/SABR) — delivering very high doses of precisely targeted radiation in three to five fractions — is the preferred treatment for Stage I NSCLC in patients who are medically inoperable or refuse surgery. Large retrospective studies show local control rates of 80–90% at three years, approaching surgical outcomes in carefully selected patients, though randomised trial data comparing SBRT directly to surgery remain limited. For patients with more advanced NSCLC, concurrent chemoradiotherapy and immune checkpoint inhibitor maintenance (durvalumab) following chemoradiation for Stage III disease represents the current standard of care.

RF ablation, microwave ablation, and cryoablation of small peripheral lung tumours are image-guided percutaneous alternatives for patients unsuitable for both surgery and SBRT, offering local control in selected cases. For benign conditions such as spontaneous pneumothorax, initial management with a chest drain and aspiration is appropriate before definitive surgical pleurodesis. Medical management of empyema with antibiotics and pleural drainage can be successful in early-stage infection, reserving surgery (decortication) for organised empyema with trapped lung.